Technology company Echo IQ (ASX:EIQ) started the integration of its EchoSolv-AS decision support software with Beth Israel Deaconess Medical Center in the US, according to a Monday filing with the Australian bourse.

EchoSolv-AS is used to assess severe aortic stenosis, a condition where the heart's aortic valve is narrowed or blocked, causing blood to have difficulty passing through.

The integration follows a trial of EchoSolv-AS by Beth Israel researchers on a group of 31,000 patients, according to the filing.

Echo IQ shares rose past 11% in afternoon trade Monday.

Price (AUD): $0.25, Change: $+0.03, Percent Change: +11.11%